Updated on 16 October 2012
What are the regulatory norms for such biologics products when they are shipped from one part of the world to another?
There is a tendency of regulatory bodies to sharpen their norms and they actively monitor products when shipped to see if the same efficacy when it was packed. In the past in the US and Europe, it has happened that some of the products were distributed in market, but there was no regulatory authority to check them. But over time, they have realized the need to check the product when they are shipped, and the regulatory landscape is improving.
What is the response of drug companies in Asia for such services?
The healthcare companies are aware of the challenge of shipping products in controlled temperature and they need specialized services. But they have to do it in a cost-efficient manner and yet comply with quality standards. The biologics shipment market is getting huge and growing. We see that few years ago such products were not available in Asia but only in Europe. Now the demand of service has grown manifold.
Do bio-pharma companies of Asia face cost pressure in shipping biologic products in specialized environment?
Biologics are always high-value and expensive products and their quality has to be controlled. The quality has to be controlled at all times. When we talk to pharma companies, cost is a concern but quality has to be supreme. They also understand that premium solution is at the higher end of costs.